Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03068234
Recruitment Status : Unknown
Verified February 2017 by RenJi Hospital.
Recruitment status was:  Not yet recruiting
First Posted : March 1, 2017
Last Update Posted : March 1, 2017
Sponsor:
Information provided by (Responsible Party):
RenJi Hospital

Brief Summary:
This study is to evaluate the efficacy and safety of an antifibrotic agent, pirfenidone as treatment of systemic sclerosis. The primary outcome of this study is improvement of skin fibrosis.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Drug: Pirfenidone Drug: Placebo oral capsule Drug: Steroids Phase 2 Phase 3

Detailed Description:

All patients enrolled should suffer from moderate to severe skin fibrosis at the screening stage.

The study period is 52 week. The study contains two stages, a 24-week blind stage following with open stage for another 24-week period of time. Subjects will receive pirfenidone or placebo randomized in the first 24-week and will all receive pirfenidone treatment in the second 24-week, with of combination of low dose steroids.

The secondary outcomes of this study include but not limit to safety, improvement of lung fibrosis and digital ulcer burden.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blinded, Placebo Controlled Study to Evaluate Clinical Efficacy and Safety of Pirfenidone for Skin Fibrosis in Systemic Sclerosis
Estimated Study Start Date : May 2017
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma
Drug Information available for: Pirfenidone

Arm Intervention/treatment
Experimental: Pirfenidone group
The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
Drug: Pirfenidone
A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.

Drug: Steroids
Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis

Placebo Comparator: Control group
The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
Drug: Pirfenidone
A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.

Drug: Placebo oral capsule
Placebo for pirfenidone capsule

Drug: Steroids
Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis




Primary Outcome Measures :
  1. Modified Rodnan Skin Score (mRSS) [ Time Frame: Week 52 ]
    A semi-quantitative score for skin fibrosis of every subjects


Secondary Outcome Measures :
  1. Modified Rodnan Skin Score [ Time Frame: Week 24 ]
    A semi-quantitative score for skin fibrosis of every subjects

  2. Assessment of chest CT [ Time Frame: Week 52 ]
    Semi-quantitative scale for fibrotic changes in chest CT images from an individual patient

  3. Assessment of chest CT [ Time Frame: Week 24 ]
    Semi-quantitative scale for fibrotic changes in chest CT images from an individual patient

  4. Forced vital capacity [ Time Frame: Week 52 ]
    A marker for lung function that may decrease with pulmonary fibrosis

  5. Forced vital capacity [ Time Frame: Week 24 ]
    A marker for lung function that may decrease with pulmonary fibrosis

  6. Diffusing capacity [ Time Frame: Week 52 ]
    Another marker for lung function that may decrease with pulmonary fibrosis

  7. Diffusing capacity [ Time Frame: Week 24 ]
    Another marker for lung function that may decrease with pulmonary fibrosis

  8. 6 minute walk test [ Time Frame: Week 52 ]
    A simple, well-accepted and quantitative clinical exam to test heart and lung function

  9. 6 minute walk test [ Time Frame: Week 24 ]
    A simple, well-accepted and quantitative clinical exam to test heart and lung function

  10. Hand function assessment [ Time Frame: Week 52 ]
    Hand function will be measured by Cochin Hand Function Scale

  11. Hand function assessment [ Time Frame: Week 24 ]
    Hand function will be measured by Cochin Hand Function Scale

  12. Proportion of subjects with increased mRSS [ Time Frame: Week 52 ]
    Proportion of subjects with ∆mRSS≥5

  13. Proportion of subjects with increased mRSS [ Time Frame: Week 24 ]
    Proportion of subjects with ∆mRSS≥5

  14. Quality of life [ Time Frame: Week 52 ]
    Assessed by the health assessment questionnaire disability index

  15. Quality of life [ Time Frame: Week 24 ]
    Assessed by the health assessment questionnaire disability index

  16. Safety and Tolerability [ Time Frame: Week 52 ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  17. Safety and Tolerability [ Time Frame: Week 24 ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fulfill EULAR/ACR classification criteria (2013) for systemic sclerosis (SSc).
  • Subjects must have mRSS≥10 at screening stage
  • Subjects must have signs of fibrosis in their chest CT at screening stage
  • If a subject has received treatments before, it should be stable at least 3 months until screening and with no significant efficacy (ΔmRSS≤-2)

Exclusion Criteria:

  • Subjects with other connective tissue diseases overlapping with SSc
  • Subjects with skin atrophy as the main cutaneous manifestation
  • Subjects with active digital ulcers or gangrene
  • Active severe SSc-driven renal disease or heart dysfunction at screening
  • Subjects with significant hematologic abnormalities
  • Abnormal liver function test at screening (ALT, AST or total bilirubin over 2 fold of upper normal level
  • Clinically significant active infection including ongoing and chronic infections
  • History of human immunodeficiency virus (HIV)
  • Confirmed Positive tests for hepatitis B or positive test for hepatitis C
  • Active tuberculosis
  • Live or attenuated vaccine within 4 weeks prior to screening
  • Subjects with significant hematologic abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03068234


Locations
Layout table for location information
China, Shanghai
RenJi Hospital
Shanghai, Shanghai, China, 200001
Sponsors and Collaborators
RenJi Hospital

Layout table for additonal information
Responsible Party: RenJi Hospital
ClinicalTrials.gov Identifier: NCT03068234     History of Changes
Other Study ID Numbers: [2017]17
First Posted: March 1, 2017    Key Record Dates
Last Update Posted: March 1, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Pirfenidone
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents